Share chart Indivior PLC
Extended chart
Simple chart
About Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. more details| IPO date | 2014-12-29 |
|---|---|
| ISIN | GB00BN4HT335 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 12.24 |
| Дивиденд ао | 0.475 |
| Сайт | https://www.indivior.com |
| Цена ао | 8.71 |
| Change price per day: | +0.487% (12.32) |
|---|---|
| Change price per week: | +6.17% (11.66) |
| Change price per month: | +9.27% (11.33) |
| Change price per 3 month: | +23.31% (10.04) |
| Change price per half year: | -18.93% (15.27) |
| Change price per year: | -18.93% (15.27) |
| Change price per 3 year: | +1 792.97% (0.654) |
| Change price per 5 year: | +12 959.07% (0.0948) |
| Change price per 10 year: | 0% (12.38) |
| Change price per year to date: | +10.73% (11.18) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Two Seas Capital LP | 13670312 | 9.96 |
| Scopia Capital Management LP | 8311367 | 6.06 |
| Vanguard Group Inc | 5846354 | 4.26 |
| Goldman Sachs Group Inc | 5683038 | 4.14 |
| FMR, LLC | 5498087 | 4.01 |
| Artemis Investment Management LLP | 3127399 | 2.28 |
| Bank of America Corporation | 2701855 | 1.97 |
| Polar Capital Holdings PLC | 2621150 | 1.91 |
| Acadian Asset Management. LLC | 2281179 | 1.66 |
| Liontrust Investment Partners LLP | 1995889 | 1.45 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Schwab International Small-Cap Equity ETF | 0.05297 | 10.07 | 3.20638 |
Vanguard FTSE All-World ex-US Small-Cap ETF
|
0.05 | 9.39 | 3.09932 |
| Dimensional International Small Cap ETF | 0.03912 | 5.69 | 3.34747 |
| Avantis International Small Cap Value ETF | 0.03727 | 14.36 | 4.23496 |
| Avantis International Equity ETF | 0.01813 | 6.46 | 3.80856 |
| Invesco FTSE RAFI Developed Markets ex-U.S. Small-Mid ETF | 0.01806 | 2.77 | 3.5165 |
| FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund | 0.01219 | 5.17 | 3.85434 |
| SPDR Portfolio Europe ETF | 0.00943 | 8.94 | 3.66537 |
| Dimensional World ex U.S. Core Equity 2 ETF | 0.00881 | 13.06 | 3.62488 |
| Dimensional International Core Equity 2 ETF | 0.00651 | 6.52 | 3.69996 |
SPDR Portfolio Developed World ex-US ETF
|
0.00638 | 5.29 | 3.28401 |
| Dimensional International Core Equity Market ETF | 0.00363 | 13.09 | 3.48343 |
| SPDR Portfolio MSCI Global Stock Market ETF | 0.00137 | 17.99 | 2.19607 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Mark Crossley | CEO & Executive Director | 2.34M | |
| Mr. Ryan Preblick | CFO & Executive Director | 1.14M | |
| Dr. Christian Heidbreder | Chief Scientific Officer | N/A | |
| Mr. Jason Thompson | Vice President of Investor Relations | N/A | |
| Ms. Cynthia Cetani | Chief Integrity & Compliance Officer | N/A | |
| Mr. Jeffrey W. Burris | Chief Legal Officer | N/A | 1972 (53 years) |
| Mr. Jon Fogle | Chief Human Resources Officer | N/A | |
| Mr. Richard Simkin | Chief Commercial Officer | N/A | |
| Mr. Hillel West | Chief Manufacturing & Supply Officer | N/A | |
| Mr. Vishal Kalia | SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer | N/A |
Address: United States, North Chesterfield. VA, 10710 Midlothian Turnpike - open in Google maps, open in Yandex maps
Website: https://www.indivior.com
Website: https://www.indivior.com
